Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a23b4904165eba68d9281c367a1cca3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bdfea1f8948897f85c6812593f1e892 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2053 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate |
2011-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2012-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce79577a0306a27146562a98e9b4b883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af03a6af5161f11173f6952777221bdf |
publicationDate |
2012-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8299019-B2 |
titleOfInvention |
Uses of modified ELR-CXC chemokine G31P to treat cancer |
abstract |
Described herein is the use of a modified human chemokine, GS-CXCL8 (3-72) K11R/G31P or G31P in the treatment of a number of cancers, including but by no means limited to prostate cancer, liver cancer and melanoma. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10561676-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018296580-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10993953-B2 |
priorityDate |
2008-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |